Development of preventive procedures against side effects and stress during TC therapy using Virtual Reality

Evaluation of the effectiveness of VR as a method of reducing side effects in TC therapy - Evaluation of effectiveness of VR during TC therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000041067

Enrollment

Registered

2020-08-01

Start date

2020-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gynecologic Cancers

Interventions

VR experience during TC therapy control

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. 20 years of age or older 2. Being admitted to the Obstetrics and Gynecology ward of our hospital 3. Undergoing TC therapy 4) Informed consent to participate in this study

Exclusion criteria

Exclusion criteria: 1. Uunder 20 years of age. 2. Visual impairment. 3. Hearing impairment 4. Prone to motion sickness or visually-induced sickness 5. Difficulty in sitting 6. Cognitive impairment

Design outcomes

Primary

Measure	Time frame
Change of ESAS-r-J scores during the 1st course	—

Secondary

Measure	Time frame
1.ESAS-r-J nausea scores and IPOS nausea/vomiting scores just before the 2nd course 2.Change of NRS scores 3.Complete response rates of nausea/vomiting 4.Outpatient transition rate for the 2nd course 5.Change of [STAI]Y-1 scores 6.Change of STAI Y-2 scores during the 1st course 7.LF/HF ratio during VR experience 8.NRS scores for side effects of VR 9.Difference in average health care costs between the two groups 10.Impressions after the VR experience on day7	—

Measure

Time frame

1.ESAS-r-J nausea scores and IPOS nausea/vomiting scores just before the 2nd course 2.Change of NRS scores 3.Complete response rates of nausea/vomiting 4.Outpatient transition rate for the 2nd course 5.Change of [STAI]Y-1 scores 6.Change of STAI Y-2 scores during the 1st course 7.LF/HF ratio during VR experience 8.NRS scores for side effects of VR 9.Difference in average health care costs between the two groups 10.Impressions after the VR experience on day7

—

Countries

Japan

Contacts

Public ContactKazuyuki Niki

Medical and Pharmaceutical Sciences Graduate School of Pharmaceutical Sciences

k-niki@phs.osaka-u.ac.jp06-6879-8250

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026